MedPath

Clinical Study Phase III, Randomized, Double-blind, Prospective and Comparative to Evaluate the Efficacy and Tolerability of Using APETIVITON BC Compared to Petivit BC in Appetite Stimulate.

Phase 3
Conditions
Inappetence
Interventions
Drug: Apetiviton BC
Registration Number
NCT01086865
Lead Sponsor
Cifarma Cientifica Farmaceutica Ltda
Brief Summary

Clinical study phase III, randomized, double-blind, prospective, comparative non-inferiority to evaluate the efficacy and tolerability of using APETIVITON BC compared to Petivit BC in appetite stimulate in children, adults and elderly.

Detailed Description

Clinical trial phase III, randomized, double-blind, prospective, comparative non-inferiority to evaluate the efficacy and tolerability of using APETIVITON BC compared to Petivit BC stimulation of appetite in children, adults and elderly. A total of 150 patients, distributed as follows:

25 patients treated children Apetiviton BC,25 patients treated children Petivit BC, (2-6 years).

25 adult patients treated with Apetiviton BC,25 adult patients treated with Petivit BC, (18-50 years.

25 elderly patients treated with Apetiviton BC,25 elderly patients treated with Petivit BC. (60-80 years.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
150
Inclusion Criteria

For both groups:

  • Patients who have inappetence;
  • Patients able to understand and maintain adherence to protocol;
  • Wash-out 20 days after ingestion of prior similar drug;
  • Patients able to understand the correct use of medication;
  • Patients who consent to participate in the study by signing the inform consent;

Children:

  • Patients of any ethnic group male and female, aged between 2 and 6 years;

Adults:

  • Patients of any ethnic group male and female, aged between 18 and 50 years;
  • Female patients in childbearing age, sexually active, make pregnancy test result should be negative and, furthermore, should be using contraceptive methods such as contraception, condom, IUD and diaphragm.

Elderly:

  • Patients of any ethnic group male and female, aged between 60 and 80 years.
  • Female patients in childbearing age, sexually active, make pregnancy test result should be negative and, furthermore, should be using contraceptive methods such as contraception, condom, IUD and diaphragm.
Exclusion Criteria

For both groups:

  • Patients with glaucoma open or closure angle;
  • Patients with predisposition to urinary retention;
  • Patients with stenous peptic ulcer or pylorus-duodenal obstruction;
  • Debilitated patients or in acute attack of asthma;
  • Alcoholic;
  • Patients who have loss of appetite caused by any serious disease;
  • Patients who make use of any drugs central nervous system depressants;
  • Patients who make use of medicines monoaminooxidase inhibitors, tricyclic antidepressants, phenothiazines, probenecid, levodopa, phenytoin, phenobarbital, chloramphenicol, cyclophosphamide, cyclosporine, chlorambucil, corticotropin, mercaptopurine, isoniazid, penicillin, estrogens, contraceptives, haloperidol, ipatrópico, barbiturates, primidone, salicylates;
  • Patients with known hypersensitivity to any components of the formula;
  • Patient who is participating in another clinical study;
  • No able to adhere to protocol;
  • Patients who are pregnant or breastfeeding;
  • Any condition that in the opinion of the investigator can impossible to include the patient's adherence to the protocol.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Petivit BCApetiviton BC-
Apetiviton BCApetiviton BC-
Primary Outcome Measures
NameTimeMethod
Evaluate the effectiveness of apetiviton BC compared to Petivit BC in appetite stimulation in children, adults and seniors.30 days
Secondary Outcome Measures
NameTimeMethod
Evaluate the tolerability of apetiviton BC compared to Petivit BC the stimulation of appetite in children, adults and seniors30 days
© Copyright 2025. All Rights Reserved by MedPath